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Abstract
Background: Inherited pathogenic variants in BRCA1 and BRCA2 are the most common causes of hereditary breast
and ovarian cancer (HBOC). The risk of developing breast cancer by age 80 in women carrying a BRCA1 pathogenic
variant is 72%. The lifetime risk varies between families and even within affected individuals of the same family. The
cause of this variability is largely unknown, but it is hypothesized that additional genetic factors contribute to differences in
age at onset (AAO). Here we investigated whether truncating and rare missense variants in genes of different DNA-repair
pathways contribute to this phenomenon.
Methods: We used extreme phenotype sampling to recruit 133 BRCA1-positive patients with either early breast cancer
onset, below 35 (early AAO cohort) or cancer-free by age 60 (controls). Next Generation Sequencing (NGS) was used to
screen for variants in 311 genes involved in different DNA-repair pathways.
Results: Patients with an early AAO (73 women) had developed breast cancer at a median age of 27 years (interquartile
range (IQR); 25.00–27.00 years). A total of 3703 variants were detected in all patients and 43 of those (1.2%) were truncating
variants. The truncating variants were found in 26 women of the early AAO group (35.6%; 95%-CI 24.7 - 47.7%) compared
to 16 women of controls (26.7%; 95%-CI 16.1 to 39.7%). When adjusted for environmental factors and family history, the
odds ratio indicated an increased breast cancer risk for those carrying an additional truncating DNA-repair variant to BRCA1
mutation (OR: 3.1; 95%-CI 0.92 to 11.5; p-value = 0.07), although it did not reach the conventionally acceptable significance
level of 0.05.
Conclusions: To our knowledge this is the first time that the combined effect of truncating variants in DNA-repair genes
on AAO in patients with hereditary breast cancer is investigated. Our results indicate that co-occurring truncating variants
might be associated with an earlier onset of breast cancer in BRCA1-positive patients. Larger cohorts are needed to confirm
these results.
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Background
Breast cancer is the most common cancer among
women with 30% of all new cancer diagnoses [1]. About
one out of eight US women will develop breast cancer
during her lifetime. It is estimated that hereditary gen-
etic factors explain 5–10% of all breast cancer cases [2].
In the mid-1990s, BRCA1 and BRCA2 [3–5] which are
part of the DNA-repair machinery [6] were identified to
play a crucial role in hereditary breast and ovarian can-
cer (HBOC) [3–5, 7, 8]. Together, pathogenic variants in
these two genes explain about 24% (95%-CI,23.4 to
24.6%) of all HBOC cases [7]. BRCA1 and BRCA2 are
functioning as genome guardians by playing a central
role in the homologous recombination repair (HRR)
pathway. Up to now, more than 300 gene products have
been associated with the DNA-repair machinery and
genome integrity maintenance of which 25 genes [8]
have been linked to HBOC.
In female BRCA1 mutation carriers, the risk of devel-
oping breast cancer by the age of 80 is 72% [9]. More-
over, the incidence of breast cancer rises quickly in early
adulthood until age 30 to 40 years in BRCA1 mutation
carriers [9]. Even though pathogenic variants in BRCA1
are associated with the highest penetrance of HBOC, the
cause for the inter-individual and even intra-familial
variation in penetrance is not clear and remains an ac-
tive field of research. This variation results in difficulties
in risk calculation and genetic counseling. Several envir-
onmental factors such as birth cohort [10], age at me-
narche [11], number of pregnancies [12], therapeutic
abortion [13], oral contraceptives [14], and prophylactic
oophorectomy [15, 16] are suspected to affect the risk of
cancer in BRCA1/2 mutation carriers. Using data from
the Generations Study, Brewer and colleagues showed
that having a first-degree female relative with breast can-
cer increases the relative risk of breast cancer as com-
pared to those without family history [17]. Moreover, the
variation in penetrance can be due to allelic variation,
which means variation in the variant type (truncating or
missense) and position within the coding region of the
BRCA1 gene [18]. As proposed by Thompson and
Easton in 2001 and 2002 and also Rebbeck et al. [19–
21], the position of the respective causative pathogenic
variant within the coding region of BRCA1/2 can change
breast or ovarian cancer risk. In this context, Rebbeck
and colleagues identified three putative “breast cancer
cluster regions” including BCCR1 which overlaps with
the RING domain of the BRCA1 protein and an “ovarian
cancer cluster region” located in exon 11 [21]. Further-
more, pathogenic variants towards the 3′-end of BRCA1
lead to a lower risk of ovarian cancer compared to breast
cancer [22].
Another cause of differences in penetrance are modify-
ing genes [18]. The Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA, http://ccge.medschl.cam.
ac.uk/consortia/cimba) screened more than 20,000 muta-
tion carriers and performed Genome Wide Association
Studies (GWAS) to identify genetic modifier loci [23–29]
and described several candidates; each adding a small part
of risk variation in BRCA1 mutation carriers (in total 2.2%
in BRCA1) [23]. The CIMBA consortium suggested using
a combination of different modifier loci to increase the
precision of risk prediction. Unlike GWAS studies that are
based on common variants, this study pursued the goal to
predict BRCA1 penetrance and AAO of breast cancer by
analysing rare variants in genes that are part of the DNA
damage response and genome integrity maintenance path-
ways as well as genes which are interacting with BRCA1.
Accurate prediction of AAO can become of clinical rele-
vance in order to prevent overtreatment of carriers who
will never develop breast cancer during their lifetime or
may develop it later in life. To address this issue, we aimed
to investigate the differences in AAO of breast cancer
among BRCA1 mutation carriers by studying 311 DNA-
repair genes which are contributing to genome stability
along with BRCA1 and BRCA2.
Methods
Selection of samples for extreme phenotype sampling
Out of more than 30,000 HBOC index cases registered
in the German Consortium for Hereditary Breast and/or
Ovarian Cancer (GC-HBOC) biobank, 133 BRCA1-posi-
tive patients either with a personal history of breast can-
cer below the age of 35 years (early AAO onset) or
without personal history of breast cancer at the age of
60 years (controls) were selected for this study. Patients
who had undergone prophylactic mastectomy or
prophylactic oophorectomy before the age of 45 years
were excluded from the analysis [30]. Participants had
signed a written informed consent and the study was
approved by the local ethics committee (ethic vote num-
ber 053/2017BO2). Relevant information regarding age
at menarche, number of pregnancies, and Oral contra-
ceptive use was collected from the GC-HBOC database.
Sequencing and data analysis
Reviewing published literature, genes were considered
on the basis of a reported breast cancer association. In
addition, all DNA-repair pathway genes were selected
from KEGG GENES database (http://www.genome.jp/
kegg/genes.html, last accessed: 26.11.2013; Additional file 1:
Table S1). A target region of 895.2 kbp consisting of 311
genes was sequenced in total. The coding regions and
exon-intron boundaries ±25 bps were targeted (using
default parameters of Agilent SureDesign, except for
Masking =Most Stringent) and enriched using Agilent
SureSelect custom RNA probes (Agilent, Santa Clara,
CA). Two hundred nanograms of genomic DNA were
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checked for quality and quantity by Qubit dsDNA Assay
(Thermo Fischer Scientific, Waltham, MA, USA) and
fragmented using a Covaris system (Covaris, Inc.,
Woburn, Massachusetts) to generate fragments of 120–
150 base pairs length. Quality and fragment size of
sheared DNA were checked using a TapeStation (Agilent,
Santa Clara, CA). Sequencing libraries were con-
structed according to the Agilent SureSelectXT proto-
col. The pre-capture and post-capture libraries were
quantified by a TapeStation. Libraries were sequenced
either on a Miseq (Illumina, San Diego CA), NextSeq500
(Illumina, San Diego CA) or HiSeq2500 (Illumina, San
Diego CA) platform using paired-end reads of 151 bps or
101 bps.
MegSAP, a free-to-use open-source bioinformatics pipe-
line was used for data analysis (version 0.1–379-gb459ce0,
https://github.com/imgag/megSAP). In brief, adapter and
quality trimming was applied using SeqPurge [31]; se-
quencing reads were mapped to the human genome ver-
sion GRCh37 with BWA (v. 0.7.15) [32], and ABRA2 [33]
(v. 2.05) was used for indel realignment; variant calling
was performed by freebayes (v. 1.1.0) [34] and variant an-
notation was done using snpEff/SnpSift (v. 4.3i) [35].
Quality control was executed on three layers of informa-
tion including raw reads, mapped reads and variants
(Additional file 2: Table S2). We used Alamut batch (v.
1.5.1, Interactive Biosoftware) for splice site annotation.
Variant interpretation
Variants were automatically classified according to an
algorithm based on a modified version of the Ameri-
can College of Medical Genetics and Genomics
(ACMG) guidelines for variant classification [36]. Ac-
cording to this algorithm, splice variants at the pos-
ition +/− 1 and +/− 2 are classified as likely
pathogenic if the variant disrupts the function of the
gene product unless the population frequency of the
variant is not compatible for a pathogenic variant
(minor allele frequency of 1% was used as a cutoff ).
For intronic variants located outside of the canonical
splice sites including Cartegni splice sites [37] we re-
ferred to Alamut Visual (Interactive Biosoftware) in-
corporated prediction tools such as MaxEntScan,
Splice Site Finder Like, and Human Splicing Finder.
Variants were considered as pathogenic or likely
pathogenic (collectively termed as pathogenic) if they
led to a truncation, initiation loss or canonical splice
site effect or if there was a relevant publication in
favor of pathogenicity and if there was additional evi-
dence in public database like ClinVar. In case there
was no evidence such as functional assessment data
available, missense, synonymous and intronic variants
were classified as variants of unknown significance
(VUS), benign or likely benign according to the
Minor Allele Frequency (MAF > 1%) in the 1000
Genomes Project (1KGP), dbSNP, Exome Aggregation
Consortium (ExAC) or ESP6500.
Statistical analysis
Descriptive statistics such as medians, means and
standard deviations for continuous data and propor-
tion and 95%-CI for categorical data was used to
characterize the study population and sequencing re-
sults. A multivariable logistic regression was carried
out to control for the potential confounding effect of
family history, age at menarche, parity, and use of
oral contraceptives. Missing data was imputed using
median or mode. The variable additional truncating
DNA-repair variants was coded as yes if the patient
carried a truncating DNA-repair variant and it was
coded as no if the patient was not carrying a truncat-
ing DNA-repair variant. The outcome was considered
the incidence of cancer. The regression analysis was
performed in R 3.5.2. Using GraphPad Prism version
6.07 for Windows (GraphPad Software, La Jolla California
USA), we performed Fisher’s exact test to compare the
mutational location in each cohort. All p-values were two-
tailed and p-values less than 0.05 were considered to be
statistically significant. Maftools was applied to visualize
BRCA1 pathogenic variants with a modified database [38].
Rare variant association study
Variants obtained from freebayes in VCF format (see
above) were annotated using the eDiVA platform
(https://ediva.crg.eu/) in order to obtain functional anno-
tation (exonic, nonsynonymous, synonymous, splicing
etc.), European population allele frequencies from 1KGP,
Exome Variant Server (EVS) and ExAC databases, as well
as functional impact scores from CADD. Variants not an-
notated as ‘exonic’ or ‘splicing’, as well as variants within
segmental duplication (SegDup identity > = 0.9) were re-
moved from further analysis. We performed sample qual-
ity control by screening for outliers in (a) number of
variants per sample and (b) transition to transversion ratio
per sample. Second, we calculated the first 10 PCA com-
ponents of all samples using only synonymous SNVs that
were not in linkage disequilibrium and had an allele fre-
quency above 0.005 in EVS. Finally, we compared the rare
variant load per gene between the early AAO cohort and
controls. No outliers were detected in any QC test and
early AAO patients and controls were clustering in a sin-
gle group in the PCA. Following QC, we removed any
variant with European AF higher than 0.01 in any of the
three databases: EVS, 1KGP, and ExAC. Additionally, we
excluded all variants annotated as synonymous or with a
CADD score below 10 (considered neutral). Using the
remaining rare, likely damaging variants we performed
Burden and SKAT-O association tests implemented in the
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R package SKAT (https://www.hsph.harvard.edu/skat/
download/) version 1.3.0. The Null model for both tests
was computed using the SKAT_Null_Model function with
output set to dichotomous outcome (out_type = “D”) and
no sample adjustment (Adjustment = FALSE). For the
SKAT-O test we used the SKATBinary function with de-
fault parameters except for method that was set to “opti-
mal.adj” (equivalent to SKAT-O method). Minor allele
frequencies (MAF) of variants transformed with Get_Lo-
gistic_Weights were used as weights. The burden test was
performed using the same function (SKATBinary) and pa-
rameters, except for method that was set to “Burden”.
Results
Participants characteristics
In total, 133 BRCA1 positive women were screened for
truncating variants in 311 DNA-repair genes. The co-
hort with early AAO consisted of 73 women who devel-
oped breast cancer at an age younger than 35 years
(median age at onset, 27 years; interquartile range (IQR)
25–27 years). The controls consisted of 60 participants,
cancer-free by the age of 60 years. Follow-up data
showed that some developed breast cancer at an age
older than 60 years (n = 25; 41.7%) with a median age at
onset of 64 years (IQR, 62–67) or had no history of
breast cancer (n = 35; 58.3% median age, 70 years; IQR,
63–75 years). The demographic characteristics of the
participants are shown in Table 1.
In total, 117 patients from both cohorts carried a
BRCA1 pathogenic single nucleotide variant (SNV), 13
patients carried a large deletion, and three patients car-
ried a large duplication in BRCA1 (Fig. 1). In the early
AAO cohort, 15.1% of all participants carried a frame-
shift founder mutation [39] in exon 20 of the BRCA1
gene (ENST00000357654: c.5266dupC:p.Gln1756fs). The
European founder missense variant [40] in exon 4
(ENST00000357654: c.181 T > G: p.Cys61Gly) was the
most frequent (10%) pathogenic variant found in the
control cohort (Additional file 3: Table S3). All patho-
genic variants in BRCA1 were confirmed by NGS.
With respect to family history, the majority of patients
in the control cohort had at least one first-degree rela-
tive with breast and/or ovarian cancer as compared to
the early AAO patients (56.2% versus 98.4%). Women
with larger families who reached older ages are expected
to have more relatives with breast and/or ovarian cancer
on average in comparison to those whose families are
smaller and younger. This can explain the difference be-
tween family history of early AAO cohort and control
cohort (Table 1).
Comparison of type and location of BRCA1 pathogenic
variants
To compare allelic variation in type and location of
pathogenic variants across the BRCA1 protein between
the early age at onset and the control cohort, we com-
pared the pathogenic variant accumulation in different
Table 1 Demographic characteristics of the population study
Early age at onset cohort Control cohort
Total Number 73 60
Breast cancer positive 100% 41.7%
Median age at onset(IQR) 27 (25–27) 64 (62–67) n = 25
BRCA1 variant location
BCCR1 (95%-CI) 13.8% (6.1–25.4%) 11.5% (4.4–23.4%)
BCCR2 (95%-CI) 8.6% (2.9–19.0%) 5.8% (1.2–15.9%)
BCCR2’ (95%-CI) 22.4% (12.5–35.3%) 15.4% (6.9–28.1%)
OCCR (95%-CI) 25.9% (15.3–39%) 42.3% (28.7–56.8%)
BRCA1 variant type % (95%-CI)
Frame-Shift-Del 26.0% (16.5–37.6%) 35.0% (23.1–48.4%)
Frame-Shift-Ins 19.2% (10.9–30.1%) 16.7% (8.3–28.5%)
Missense variant 8.2% (3.1–17.0%) 13.3% (5.9–24.6%)
Nonsense variant 26.0% (16.5–37.6%) 21.7% (12.1–34.20%)
Splice-Site variant 5.5% (1.5–13.4%) 5.0% (1.0–13.9%)
CNV 15.1% (7.8–25.4%) 8.3% (2.8–18.4%)
Family History
Data available for
73 (100%) 60 (100%)
First-degree relative with Breast and/or Ovarian cancer 41 (56.2%) 59 (98.4%)
BCCR Breast cancer cluster region, BCCR1 c.179–505, BCCR2 c.4328–4945, BCCR2’ c.5261–5563, OCCR c.1380–4062, Del Deletion, Ins Insertion, CNV Copy
number variation
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regions of BRCA1. Whereas no differences were de-
tected for the Breast Cancer Cluster Regions (BCCRs),
which are associated with increased risk of breast cancer
(Additional file 4: Figure S1a), differences were found for
the Ovarian Cancer Cluster Region (OCCR). 22 (45.3%)
patients in the control cohort (Fig. 1, Table 1) carried a
pathogenic variant within the OCCR compared to 15
(25.9%) of patients in the early AAO cohort, though the
statistical significance was not reached (p-value = 0.07).
Patients with large deletions or insertions and splice site
variants were excluded from this analysis since they ei-
ther span more than one region or their impact on pro-
tein function is not certain, respectively. In the early
AAO cohort, 56 patients (76.7%; 95%-CI 65.4 to 85.3%) of
BRCA1 mutation carriers carried a truncating variant
while 6 patients (8.2%; 95%-CI 3.1 to 13.3%) carried a mis-
sense pathogenic variant (ENST00000357654: c.181 T >G:
p.Cys61Gly) and 11 patients (15.1%; 95%-CI 7.8 -25.4%)
carried a copy number variation (CNV). In contrast, 47
patients (78.3%; 95%-CI.65.8% to 87.9) carried a truncating
variant in controls, 8 patients (13.3%; 95%-CI 5.9 to
24.6%) carried a missense pathogenic variant (Additional
file 4: Figure S1b) including ENST00000357654: c.181 T >
G: p.Cys61Gly, and c.5096G > A: p.Arg1699Gln and 5 pa-
tients (8.3%; 95% CI 2.8 to 18.4%) carried a CNV.
Truncating germline variants in DNA-repair genes
We evaluated 311 genes that maintain genome integ-
rity and/or have been associated with HBOC. The
mean sequencing depth was 456x ± 197.3 SD. Additional
Fig. 1 BRCA1 pathogenic variants. X axis shows the amino acid position and functional domains of the BRCA1 protein. Each lollipop represents a
pathogenic variant and the type of variant is depicted with different colors. The Y axis demonstrates the number of mutation carriers. The
Horizontal bars show the copy number variation. Deletion (red) and duplication (purple) is depicted by different colors. Breast cancer Cluster
Regions (BCCRs) are shown as black bars and Ovarian Cancer Cluster Region (OCCR, Rebbeck and colleagues [21]) are depicted in dark blue.
Splice-site variants are not shown
Sepahi et al. BMC Cancer          (2019) 19:787 Page 5 of 12
file 2: Table S2 shows the detailed results and quality pa-
rameters of sequencing. A total of 3703 variants was iden-
tified and of those 43 (1.2%) truncating variants
(Additional file 5: Table S4) were detected in 36 DNA-re-
pair genes. The affected genes were mainly Single Strand
Break Repair genes (SSBR, 30.6%), Double Strand Break
Repair genes (DSBR, 30.6%), and check-point factor genes
(11.1%). The remaining truncating variants were identified
in genes with other functions such as BRCA1/2 interac-
tors, centrosome formation and signal transduction. In
overall, 42 women had at least one additional DNA-repair
truncating variant. In the early AAO cohort, 26 out of 73
patients (35.6%; 95%-CI 24.7 - 47.7%) carried at least one
additional truncating variant and two cases carried two
additional truncating variants in DNA-repair genes
(Additional file 6: Figure S2a). Among controls, 16 out of
60 participants carried an additional DNA-repair germline
truncating variant (26.7%; 95%-CI 16.1 to 39.7%). In this
cohort, three participants carried two germline DNA-re-
pair truncating variants; at least one of them affected a
DSBR pathway gene (Additional file 6: Figure S2b).
We investigated the effect of additional DNA-repair
truncating variants on the risk of developing breast can-
cer among BRCA1 mutation carriers, adjusted for age at
menarche, oral contraceptive use, parity and family his-
tory. Despite the fact that it did not reach the conven-
tionally accepted p-value of 0.05, the odds ratio is in
favor of increased breast cancer risk for double heterozy-
gote patients (OR: 3.1; 95% CI 0.92 to 11.5, p-value =
0.07). To confirm the validity of our model, the same
analysis was carried out on a subset of subjects who
were matched for family history (early AAO cohort; n =
41 and control cohort; n = 59) adjusted for age at menar-
che, oral contraceptive use and parity (OR: 3.3; 95%-CI
0.92 to 13.3; p-value = 0.07). Consistent results were ob-
tained for this subset of cohorts.
To test the effect of additional truncating variants
in specific DNA-repair pathways, we compared the
mutational load in DSBR and SSBR genes between
the two cohorts. Among the early AAO cohort, 8/73
women (11.0%; 95%-CI 4.9 -20.5%) carried an add-
itional truncating variant in DSBR compared to 5/60
women (8.3%; 95%-CI 2.8 -18.4%) in the control co-
hort. Regarding the SSBR genes, we found 8/73
women (11.0% %; 95%-CI 4.9 -20.5%) in the early
AAO cohort carrying additional SSBR truncating vari-
ants as compared to 5/60 women (8.3%; 95%-CI 2.
%-20.5) in the control cohort. The mutational load in
DSBR and SSBR did not differ between both cohorts
(Fig. 2). Further comparison has been carried out be-
tween SSBR- and DSBR- mutation carriers with non-
carriers (Additional file 7: Figure S3; Additional file 8:
Table S5). In none of the cases differences were sta-
tistically significant.
Pathological characteristics
Among control cohort, 25 (41.7%) patients developed
breast cancer at a median age of 64. For these pa-
tients the tumor characteristics were compared with
the tumor characteristics of the early AAO patients.
The immunohistochemical staining of estrogen and
progesterone receptors did not differ significantly with
respect to the AAO, though the ER and PR negativity
was more frequently found in the early AAO cohort
compared to affected control patients (p-value = 0.28
and 0.76 respectively, Table 2). Tumors of the early
AAO group tended to show a higher histological
grade compared to the tumors of the affected control
patients (Table 2) although the difference failed to
reach the significant level (p-value = 0.24). Expression
of estrogen and progesterone receptors, grading of tu-
mors and histological types of tumors were not sig-
nificantly different between patients with additional
truncating variants in DNA-repair genes and patients
without additional DNA-repair truncating variants
(Additional file 9: Table S6).
Rare variant association study (RVAS)
To assess the load of rare missense (VUS + pathogenic
variants) variants in DNA-repair genes on the AAO
of breast cancer in BRCA1-positive patients we per-
formed a Burden test and a SNP-set (sequence)
Kernel Association Test (SKAT-O). To this end, a
comprehensive quality control of early AAO cohort
and controls was done (see Methods). No differences
were observed between early AAO cohort and con-
trols in (a) variants per sample, (b) rare variant load
per gene, (c) transition-transversion ratio, and (d) top
10 PCA components. Next, we removed all common
variants (MAF > 1% in EVS, 1KGP, or ExAc) as well
as all synonymous variants from both early AAO and
control cohort. To search for genes conveying an in-
creased risk, we used patients of the early AAO
cohort as cases and patients of the late AAO cohort
as controls (Additional file 10: Table S7). Although
there was no significant gene identified after FDR
correction, several genes showed significant un-cor-
rected p-values in at least one of the two RVAS tests,
requiring more investigation in independent larger co-
horts. These candidate genes include MYBBP1A (early
AAO: 13, controls: 3), MRE11 (7:0), TDG (5:0), WRN
(7:1), TP53BP1 (10:3) and REV1 (8:2) as well as one
potential risk reducing factor, PTCH1 (early AAO: 1,
controls: 8).
Patients with both heterozygous pathogenic variants in
BRCA1 and BRCA2
Interestingly, two cases carrying pathogenic variants in
both BRCA genes were found in either cohort. Case 1
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was a patient affected with breast cancer at the age of
26 yrs. She had two first-degree relatives with breast can-
cer. There was no ovarian cancer and no second-degree
relative with any type of cancer. She carried a BRCA1
pathogenic variant (ENST00000357654: c.1016dupA)
and an additional BRCA2 pathogenic variant
(ENST00000544455.1: c.3585_3686delAAAT). Unfortu-
nately, tumor characteristics were not available for this
patient. Case 2 was diagnosed with breast cancer at the
age of 63.9 years. Her family history was indicative for
HBOC: A first-degree relative with breast cancer and
three first-degree relatives with ovarian cancer. Also, there
was a second-degree relative with breast cancer. She
carried a nonsense variant in BRCA1 (ENST00000357654:
c.1687C > T) and a nonsense variant in BRCA2
(ENST00000544455.1: c.8875G > T). An additional trun-
cating variant was found in EME2, (ENST00000568449:
c.541_544delGCTG) a DSBR gene. The immunohisto-
chemical staining showed a triple negative tumor.
Discussion
Genome-wide case control association studies identified
susceptibility variants and modifiers of penetrance for
BRCA1 mutation carriers [23, 25–29]. Despite the fact
that each modifier explains a small proportion of genetic
variation of breast cancer development in carriers of
Fig. 2 Distribution of carriers of additional DNA-repair mutation in each cohort regarding the type of pathway. 43 truncating variants were
detected in 36 DNA-repair genes. These truncating variants mainly affected double-strand break repair (DSBR), single-strand break repair (SSBR),
BRCA1/2 interactors, centrosome formation, and check-point factors. No significant difference was found in DSBR, SSBR, BRCA1 / BRCA2 interactors,
checkpoint factors and other pathways mutational load between the two cohorts. Two cases in the early AAO cohort carried an additional
mutation in BRCA1 / BRCA2 interactor genes while no mutation acrrier in these genes was found in control cohort. The width of each block
referes to the porportion of mutated pathway among all mutated pathways and the hight of each block referes to the porportion of mutated
samples in each cohort. Mutated genes in each pathways are shown in boxes
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BRCA1 pathogenic variants [23], still a large proportion
of risk variation is unknown. The effect of each modify-
ing variant can be combined into poly genic risk scores
(PRSs), which may confer larger relative risks [25, 41].
The approach taken in this study was to enrich for rare
variants via preferentially selecting the carriers who are
most informative cases [42]. For this reason, the extreme
ends of age at onset of hereditary breast cancer were
chosen and we aimed to identify differences in the muta-
tional load in these two highly selected cohorts. We hy-
pothesized that inherited truncating variants in DNA-
repair genes, which are partner components of BRCA1
in the maintenance of genome integrity, are likely to
interact with BRCA1 by reducing the age at onset of her-
editary breast carcinoma.
Previously reported by Thompson and Easton in 2001
and subject of a more recent study by Rebbeck et al.
(2015), it was found that allelic variation in BRCA1
pathogenic variants is one of the reasons of variation in
risk for breast cancer compared to ovarian cancer in
HBOC patients. Rebbeck and colleagues described mul-
tiple regions associated with a higher risk for breast can-
cer compared to ovarian cancer (breast cancer cluster
regions = BCCRs) and, one region with an increased risk
for ovarian cancer compared to breast cancer (OCCR)
[19–21]. The mutational position comparison in our
cohorts showed no difference for BCCRs but a non-sig-
nificant higher variant load in the OCCR (p-value = 0.07)
among controls. Although the difference was not statisti-
cally significant, it is worth considering that pathogenic
variants in OCCR not only lead to increased risk of
ovarian cancer but they also decrease the risk of breast
cancer [21]. Regarding the variant type, there was no dif-
ference in truncating or missense variants distribution in
each cohort. While the most common pathogenic missense
variant in both cohort was ENST00000357654: c.181 T >
G: p. Cys61Gly, the missense variant ENST00000357654:
c.5090G >A: p.Arg1699Gln was exclusively found in two
of the patients in the control cohort. This is in line with
previous reports where this variant had reduced cumula-
tive risk of breast cancer by age 70 to 20% [43, 44].
Concerning the sum effect of truncating DNA-repair
variants on the risk of breast cancer among BRCA1 mu-
tation carriers, our results are suggesting an increase in
the breast cancer risk for the BRCA1 mutation carriers
who carry additional truncating DNA-repair variants
(OR: 3.1; 95% CI 0.92 to 11.5; p-value = 0.07). The small
number of old cancer-free BRCA1 mutation carriers was
a limiting factor in this study. The sum effect of patho-
genic variants in DNA-repair genes can lead to a differ-
ent cancer phenotype as shown by Pritchard and
colleagues [45] who reported a higher prevalence of
Table 2 Histopathological characteristics of tumors
Early AAO cohort
Number (%)
Affected controls
Number (%)
P value
Histological Type
Data available
62 out of 73 22 out of 25
Ductal 53 (85 .5%) 22 (100%) 0.10
Medullary 6 (9.7%) 0
Lobular 2 (3.2%) 0
Others 1 (1.6%) 0
Histological grade
Data available
66 out of 73 22 out 25
Grade III 53 (80.3%) 14 (63.7%) 0.24
Grade II 13 (19.7%) 7 (31.8%)
Grade I 0 1 (4.5%)
Steroid receptors
Data available
64 out of 73 22 out 25
ER negative 47 (73.4%) 13 (59.1%) 0.28
PR negative 52 (81.3%) 17 (77.3%) 0.76
Human Epidermal Receptor
Data available
52 out of 73 19 out of 25
HER2/neu negative 49 (94.2%) 17 (89.5%) 0.60
Triple Negative Breast Cancer
Data Available
55 out of 73 20 out of 25
TNB 32 (58.2%) 11 (55%)
Data were available for 67 out of 73 patients in the early age at onset cohort and from 25 cases that developed breast cancer in control cohort
ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2
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germline DNA-repair pathogenic variants in metastatic
prostate cancer patients compared to localized prostate
cancer. More recently, Brohl and colleagues [46] re-
ported a significantly higher frequency of germline
DNA-repair pathogenic variants in patients with Ewing
sarcoma in comparison with general population. By
pathway analysis they uncovered that hereditary breast
cancer genes, and remarkably, genes involved in DSBR
were highly mutated.
Despite the small sample size, we carried out a rare
variant association study (RVAS) using SKAT-O and
Burden tests to shed light on the role of rare variants in
the genetic risk of hereditary breast cancer. The results
of SKAT-O and Burden tests were not statistically sig-
nificant after multiple testing corrections. The top
ranked gene in the Burden test is MRE11. Mre11 is a
member of MRN (MRE11, RAD50, and NBS1) complex
[47]. This complex is involved in the sensing of DNA
double strand breaks and it initiates the processing of
double strand break repair [48–50]. Studies showed that
hypomorphic mutations in MRE11 and NBS1 lead to
Ataxia telangiectasia disorder and Nijmegen breakage
syndrome, a rare autosomal recessive disorder [51, 52].
Pathogenic variants in the MRN complex were also
linked to cancer predisposition. Recently Gupta and col-
leagues showed an association between triple negative
breast cancer and MRE11 defects [53]. The top ranked
gene in SKAT-O test and the third top ranked gene in
burden test is MYBBP1 which inhibits colony formation
and tumorigenesis and enhances the anoikis in a p53
dependent manner [54].
We also evaluated the tumor histology and immuno-
histochemical characteristics of the tumors and whether
they were influenced by AAO among BRCA1 mutation
carriers. Although the clinicopathological features of
BRCA1 associated breast tumors are studied widely and
previous studies showed that BRCA1 positive tumors
demonstrated higher tumor grade, lower estrogen recep-
tor expression, and lower progesterone receptor expres-
sion [55–57], the status of ER and PR expression among
young and older BRCA1 associated breast cancer pa-
tients is less well studied. Vaziri and colleagues [58] ob-
served that the ER and PR negativity was more common
in BRCA1-positive patients with an age at onset younger
than 50 years compared to above 50 years of age. In
2005, Eerola and colleagues [59] showed similar results
by studying BRCA1/2 positive families in comparison
with BRCA1/2 negative families. They observed a signifi-
cant difference in ER negativity for BRCA1 positive, pre-
menopausal patients (age of diagnosis below 50 years).
These patients also suffered from higher-grade tumors
compared to postmenopausal patients. Our results also
demonstrate that carrying a truncating variant in DNA-
repair genes in addition to a BRCA1 pathogenic variant
does not change tumor characteristics since the differ-
ences in histology and histochemical features of tumors
did not differ in those with additional truncating variants
in DNA-repair genes compared to those without.
As part of the study we also identified double hetero-
zygotes for pathogenic BRCA1 and BRCA2 variants.
While the frequency of pathogenic variants in BRCA1
and BRCA2 is high in the Ashkenazi Jewish population
[60, 61], it was found that 0.3% of all Ashkenazi Jewish
breast cancer patients were double heterozygotes for
BRCA1/2 pathogenic variants [62]. In contrast, double
heterozygosity for the two major breast cancer genes is
expected to be less common phenomenon in other pop-
ulations. Several studies reported double heterozygous
females including a report by Heidemann and col-
leagues (2012), showing that double heterozygotes
were not younger at the time of first diagnosis com-
pared to other patients. Interestingly, they reported a
more severe phenotype in double heterozygote fe-
males in comparison with their single heterozygote
relatives [63]. In the present study, we identified two
cases with double heterozygosity in BRCA1/2. One of
them was found in early AAO cohort whereas an-
other double heterozygote BRCA1/2 female had a late
breast cancer manifestation. These results advocate
panel testing, since panel testing allows detection of
variants in different genes simultaneously. The pres-
ence of additional truncating variants is also of high
relevance for the families and segregation analysis
should be offered in families with known pathogenic
variants to identify patients with high risk for cancer
predisposing syndromes.
Conclusions
In the last few years, several attempts were made to
elucidate the variable penetrance of BRCA1 patho-
genic variants. GWA analyses identified several loci,
which can modify the penetrance of BRCA1/2 patho-
genic variants and the age at onset of hereditary
breast and ovarian cancer to some extent. To our
knowledge, this is the first time that germline trun-
cating variants in DNA-repair pathways were studied
for their effect on age of breast cancer onset among
BRCA1 carriers. The odds ratio observed in this study
indicates a potential effect of co-occurring DNA-re-
pair truncating variants and pathogenic variants in
BRCA1 on the earlier onset of breast cancer. Limita-
tions of this study are the small sample size due to
low numbers of asymptomatic BRCA1 mutation car-
riers and the large number of missense variants in
DNA-repair genes which are of uncertain significance.
Further studies and larger cohorts are needed to con-
firm the results obtained in this study.
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